Amgen, Bristol-Myers Squibb, Pfizer and Sanofi-Aventis Conducting R&D on Protein-Based Therapies for Oncology Conditions:

LONDON--(BUSINESS WIRE)-- Metabolic disorders, oncology and central nervous system disorders attract the highest number of molecules at late stage development, according to a new report available on companiesandmarkets.com. Of these, oncology drugs represent 37% of total product pipeline activity, as there is a strong unmet need for effective, well tolerated cancer treatments.

Comparative Analysis of Late Stage Pipeline Molecules in Major Indications - Oncology Pipeline Leads with Most Promising Molecules in Late Stage Development

http://www.companiesandmarkets.com/Market-Report/comparative-analysis-of-late-stage-pipeline-molecules-in-major-indications-oncology-pipeline-leads-with-most-promising-molecules-in-late-stage-development-624017.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2

There are a number of companies which are conducting R&D on protein-based therapies for oncology conditions, including Amgen, Bristol-Myers Squibb, Pfizer and Sanofi-aventis. Protein therapies have been seen to induce fewer debilitating side-effects when compared with existing chemotherapy treatments.

Tyrosine kinase inhibitors are the most common type of drugs undergoing Phase II and III trials, with around 40% of all Phase III oncology trials involving molecules of this nature. Kinase inhibitors are also being developed for treatment of diabetes, autoimmune diseases and restenosis, amongst others.

Vaccines, mTOR inhibitors and Cytochrome P450 inhibitors also have a strong present in the late stage development pipeline.

The drug discovery pipeline includes 174 ‘me too’ therapies to treat type II diabetes, which have the same or similar action as existing drugs. These drugs sometimes offer additional benefits, such as improved safety and efficacy. Examples of these include glucagon-like peptide-1 (GLP-1) analogues and glitazones.

The 132 page late stage drug pipeline research report was published in July 2011, and provides a comprehensive review and analysis of late stage pipeline molecules for several conditions. The report also compares drugs in development for major indications by therapy area, phase, unmet need, safety, efficacy, mechanism of action, stage of target disease and technology trends. Drugs with blockbuster potential are identified, and forecast sales of oncology treatment drugs to 2017 are also provided.

Report Details:

http://www.companiesandmarkets.com/Market-Report/comparative-analysis-of-late-stage-pipeline-molecules-in-major-indications-oncology-pipeline-leads-with-most-promising-molecules-in-late-stage-development-624017.asp?prk=7c4ed5b510c1ffe12b50d9829eddaba2



CONTACT:

Paul Chapman
Press Office
Companies & Markets
[email protected]
London (UK): +44 (0) 203 086 8600

KEYWORDS:   United Kingdom  Europe

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Communications  Marketing

MEDIA:

Logo
 Logo

Suggested Articles

Pillar is bankrolling a new accelerator for budding biotechs. Petri aims to serve biotech startups at the “frontier of biology and engineering.”

One of the last major, late-stage attempt at stopping Alzheimer’s using a BACE inhibitor has ended up on the trash pile with so many others.

The oligosaccharide microbiome modulator was no better than placebo at reducing lactose intolerance symptoms.